GLP-1 & Metabolic Research Peptides
- Semaglutide 4mg vial (2mg/ml) 2mls $147
- Retatrutide 16mg Vial (16mg/ml) 1ml $174
- Retatrutide 32mg Vial (16mg/ml) 2mls $276
- Tirzepatide 20mg Vial (10mg/ml) 2mls $204
- Tirzepatide 30mg Vial (15mg/ml) 2mls $228
-
Tirzepatide 60mg Vial (30mg/ml) 2mls $300
Explore three metabolic peptides that target pathways involved in appetite regulation, blood sugar control, insulin response, and energy metabolism. While each works differently, all three are being studied for their effects on metabolic health and weight management.
Semaglutide (SEMA) — GLP-1 Receptor Agonist
Targets the GLP-1 receptor to help regulate appetite, increase feelings of fullness, slow gastric emptying, and support blood sugar control. Semaglutide is a single-receptor agonist.
Tirzepatide (TIRZ) — Dual GIP/GLP-1 Receptor Agonist
Activates two metabolic hormone receptors, GIP and GLP-1. This dual action influences appetite, insulin response, blood sugar regulation, and weight management. Clinical trials have demonstrated substantial weight-loss effects.
Retatrutide (RETA) — Triple GIP/GLP-1/Glucagon Receptor Agonist
An investigational triple-receptor agonist targeting GIP, GLP-1, and glucagon pathways. Researchers are studying its potential effects on appetite, energy expenditure, fat metabolism, and body weight.
Important Information
Semaglutide and tirzepatide have FDA-approved prescription formulations for specific indications. Retatrutide remains investigational and is not FDA-approved. Research-grade products are not equivalent to FDA-approved medications and should not be used for human consumption.